Protein Calorie Malnutrition and Cancer Therapy

Drug Safety

Volumn 7, Issue 6, 1992, Pages 404-416

  Parnes, Howard L ^a   Aisner, Joseph ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; ANABOLIC AGENT; ANTINEOPLASTIC AGENT; CYTOKINE; HYDRAZINE SULFATE; INSULIN; MEGESTROL; NANDROLONE DECANOATE; RECOMBINANT GROWTH HORMONE;

ANOREXIA; CACHEXIA; CANCER CHEMOTHERAPY; CANCER THERAPY; CARBOHYDRATE METABOLISM; HUMAN; MALNUTRITION; PROTEIN INTAKE; PROTEIN METABOLISM; REVIEW; TOTAL PARENTERAL NUTRITION;

ANOREXIA; CACHEXIA; COMBINED MODALITY THERAPY; HORMONES; HUMAN; HYDRAZINES; MEGESTROL; NEOPLASMS; PARENTERAL NUTRITION, TOTAL; PROTEIN-ENERGY MALNUTRITION;

EID: 0026450967     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199207060-00003     Document Type: Article

References (91)

1. Cachectin/tumor necrosis factor production by cancer patients
2. Carboplatin in head and neck cancer
3. Reversible abnormalities in phagocytic function in poorly controlled diabetic patients
4. Cachectin: more than a tumor necrosis factor
5. Some practical and theoretic concepts in the nutritional assessment of the cancer patient
6. Cellular immunity in semistarved states in hospitalized adults
7. Prevalence of malnutrition in general medical patients
8. Cancer cachexia
9. Uncomplicated starvation versus cancer cachexia
10. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
11. Perioperative total parenteral nutrition in surgical patients
12. Insulin and acivicin improve host nutrition and prevent tumor growth during total parenteral nutrition
13. Hydrazine sulfate in cancer patients with weight loss
14. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss
15. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer
16. Effect of adjuvant central Iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer a randomized trial
17. Intravenous hyperalimentation and cancer a historical perspective
18. Nutrition, cancer, and intravenous hyperalimentation
19. Effect of intravenous hyperalimentation on established delayed hypersensitivity in the cancer patient
20. Intravenous hyperalimentation as an adjunct to cancer chemotherapy
21. Cachexia, the metabolic component of neoplastic diseases
22. Perioperative parenteral nutrition: a meta-analysis
23. Anorexia as a general effect of cancer
24. Prognostic effect of weight loss prior to chemotherapy in cancer patients
25. Interleukin-I and the pathogenesis of the acute phase response
26. The effects of total parenteral nutrition of immunodepression due to malnutrition
27. Alterations in serum levels, anti-tumor activity and toxicity of methotrexate in rats after a short period of nutritional depletion
28. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding
29. What’s new in general surgery - cancer cachexia
30. Current concepts in immune derangement due to undernutrition
31. Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat
32. Effect of nutritional status on the hepatobiliary excretion of methotrexate in the rat
33. Symptoms influencing food intake in cancer population: correlations with primary site, caloric intake, and nutritional status. Abstract no. 1002
34. Megestrol acetate-induced differentiation of 3T3-LI adipocytes in vitro
35. Effects of total parenteral nutrition on marrow recovery during induction for acute non-lymphocytic leukemia in childhood
36. Pathophysiology of malnutrition in the adult cancer patient
37. Effect of cytotoxic agents on protein kinetics in patients with metastatic cancer
38. Modulation of cellular immunity in malnutrition: effect of interleukin 1 on suppressor T cell activity
39. Altered glucose metabolism in metastatic carcinoma
40. General metabolic abnormalities in cancer patients: anorexia and cachexia
41. Correlation of tumor necrosis factor and prostaglandin E2 production of monocytes in bladder cancer patients
42. Protection against chemotherapy toxicity by Iv hyperalimentation
43. Total parenteral nutrition and cancer clinical trials
44. Energy expenditure in malnourished cancer patients
45. Cisplatin. vinblastine and hydrazine sulfate (NSC #1500141 in advanced non-small lung cancer (NSCLC): a randomized, placebo controlled, double blind phase III study
46. Symptomatology and diagnosis of gastric cancer
47. Cancer chemotherapeutic response and intravenous hyperalimentation
48. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia
49. Tumor necrosis factor and other cytokines in the pathogenesis of cancer cachexia
50. Cancer of the stomach
51. Fat metabolism and cancer
52. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis
53. Interleukin I and tumor necrosis factor do not regulate protein balance in skeletal muscle
54. Insulin reversal of cancer cachexia in rats
55. Control of food intake in cancer cachexia: a challenge and a tool
56. Preoperative parenteral feedings in patients with gastrointestinal carcinoma
57. Protein-calorie undernutrition in hospitalized cancer patients
58. Effect of total parenteral nutrition on survival in advanced colon cancer
59. Parabiotic transfer of cancer anorexia/cachexia in male rats
60. Nutrient intake and nitrogen metabolism in cancer patients during oncological chemotherapy
61. The potential of megestrol acetate in the treatment of cancer cachexia
62. A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer
63. Role of biochemical mediators in clinical nutrition and surgical metabolism
64. A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance
65. Cancer of the esophagus
66. IV hyperalimentation and chemotherapy for stage III testicular cancer: a randomized study
67. Cachexia of malignancy: potential role of insulin management
68. Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors
69. Follow-up of a randomized trial for oat cell carcinoma: evaluating the efficacy of peripheral intravenous nutrition as adjunct treatment
70. A prospective, randomized study of adjuvant parenteral nutrition in the treatment of sarcomas: results of metabolic and survival studies
71. Parenteral nutrition in the surgical patient
72. Nutritional problems associated with gastrointestinal and genitourinary cancer
73. Alteration of 5-fluorouracil metabolism by protein calorie malnutrition. Abstract no. 2143
74. Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil
75. Nutritional concerns in cancer patients
76. Neutrophil dysfunction in diabetes mellitus
77. High-dose megestrol acetate: a possible treatment for cachexia
78. Megestrol acetate in cancer anorexia and weight loss
79. Anorexia-producing intermediary metabolites
80. Reduction of methotrexate toxicity with improved nutritional status in tumor-bearing animals
81. Enhanced tumor response to phase-specific chemotherapy by parenteral amino acid administration
82. Enhanced tumor response to cycle-specific chemotherapy by pulse total parenteral nutrition
83. Cachectin: a hormone that triggers acute shock and chronic cachexia
84. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation
85. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection
86. Immediate causes of death in cancer
87. Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer
88. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation
89. Energy metabolism and requirements in the cancer patient
90. Monocyte TNF production in gastrointestinal cancer
91. Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition